PAZINIB 400 mg Tablets
PAZINIB 400 mg Tablets PAZINIB contains Pazopanib, a multi-targeted receptor tyrosine kinase (RTK) inhibitor. It functions by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-KIT), thereby suppressing tumor angiogenesis, cellular proliferation, and blood vessel formation. It is indicated for treating advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients previously treated with chemotherapy.
| Brand | PAZINIB |
| Storage Temperature | Store below 30°C in a dry place (Protect from light and moisture) |
| Prescription Needed | Yes |
| Composition | Pazopanib Hydrochloride equivalent to Pazopanib |
| Strength | 400 mg |
| Form | Film-coated Tablets |
| Pack Size | 30 Tablets |
| Packaging | Bottle containing 30 Tablets |
| Country of Origin | Made In India |
| Manufacturer | Hetero Healthcare Limited |
PAZINIB 400 mg Tablets
PAZINIB 400 mg Tablets PAZINIB contains Pazopanib, a multi-targeted receptor tyrosine kinase (RTK) inhibitor. It functions by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-KIT), thereby suppressing tumor angiogenesis, cellular proliferation, and blood vessel formation. It is indicated for treating advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients previously treated with chemotherapy.
Related Products
-
-
CAPSY 500 Tablets
-
CELDAZ 200 Injection
-
CETUXA
-
Cycloxan 50
-
Duxocin 50 Injection
-
Dyronib 20 Tablets
-
Dyronib 50 Tablets
-
Dyronib 70 Tablets
-
Glenza 80 mg
-
Hertraz 150
-
Hertraz 440
-
PALBOCIB-125 Capsules
-
PAZEQOL-200 Tablets
-
PAZEQOL-400 Tablets
-
PAZINIB 200 mg Tablets
-
PICLIB 100 mg Capsules
-
PICLIB 75 mg Capsules